References
- Thresher A, Foster R, Ponting DJ, Stalford SA, Tennant RE, Thomas R. Are all nitrosamines concerning? A review of mutagenicity and carcinogenicity data. Regulatory Toxicology and Pharmacology. 2020; 116.
- Malihi F, Wang T. An improved analytical method for quantitation of nitrosamine impurities in ophthalmic solution using liquid chromatography with tandem mass spectrometry. Chrom Open J. 2022; 2:100037.
- Control of nitrosamine impurities in human drugs: Guidance for industry, U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER). 2020.
- EMA/369136/2020 Committee for Medicinal Products for Human Use. Nitrosamine impurities in human medicinal products.
- ICH M7 Principles- Impurity identification and control EMA sartans with N-nitrosamine impurities.
- Zheng L, Radich CL, Gong X, Liang X, Mowery MD. A practical HPLCMS method for the analysis of nitrosamine drug substance related impurities using an inexpensive single quadrupole mass spectometer. J Chromatograph.A, 2024; 1736:465399
- Manchurik M, Shaik MA, Gopireddy VSR, Sultana N, Gogineni S. Analytical Methodologies to detect N-Nitrosamine impurities in active pharmaceutical ingredients, drug products and other matrices. Chem Res Toxicol, 2024; 37(9):1456-1483
- Gushgari AJ, Halden RU. Critical review of major sources of human exposure to N-nitrosamines. Chemosphere. 2018; 210: 1124-1136.
- Tricker R, Preussmann R. Carcinogenic N-nitrosamines in the diet: occurrence, formation, mechanisms and carcinogenic potential. Genetic Toxicology. 2018; 259:277-289.
- Ji Y, Guo R, Lee FS, Li TFS. Rapid determination of trace level N-nitrosamine precursors in secondary-treated wastewater by using two dimensional-ion chromatography. Journal of Hazardous Materials. 2019; 368:452-458
- Zhu M, Ye Q, Zhou T, Chen L, Yu L, Li B, Hu J. Determination of 10 volatile N-nitrosamines in meat products by gas chromatography-tandem mass spectrometry. Chinese Journal of Chromatography. 2019; 37(2):207-215
- Sonali SB. Critical analysis of drug product recalls due to nitrosamine impurities. J Med Chem. 2021; 64(6): 2923-2936
- Amararathna M, Hoskinb DW, Rupasinghe VHP. Anthocyanin-rich haskap (Lonicera caerulea L.) berry extracts reduce nitrosamine-induced DNA damage in human normal lung epithelial cells in vitro. Food and Chemical Toxicology. 2020; 141: 111404
- European Pharmacopoeia EuPh – N nitrosamines in active substances. 2020.
- Control of Nitrosamine Impurities in Human Drugs, February 2021, US food and drug administration Guidance for Industry, Revision 1
- Update on nitrosamine impurities: EMA continues to work to prevent impurities in medicines, EMA/241020/2019, 26th April 2019
- Li Y, Hecht SS. Metabolic activation and DNA interactions of carcinogenic N-nitrosamines to wich humans are commonly exposed. Int Mol Sci J. 2022; 23:455
- Vikram HPR, Kumar TP, Kumar G, Beereka NM et al. Nitrosamines crisis in pharmaceuticals-insights on toxicological evaluation, risk assessment and analytical challenges, J Pharm Anal. 2024; 14(5): 1-14
- Nudelman R, Kocks G, Mouton B, Ponting DJ et al. The nitrosamine “saga” : lessons learned from five years of scrutiny. Org Process Rev. 2023; 27: 1719-1735
- Hinz J, Mekonnen TF, Bergrath J, Sewell S, Schneck Y, Wirtz M, Telgheder U. Analysis of nine nitrosamines relevant to occupational safety by ion mobility spectrometry. J of Chromatography Open. 2023; 4:1-7
- Bharate S.S. Critical analysis of drug product recalls due to nitrosamine impurities. J Med. Chem. 2021; 64: 2923–2936
- Lim DS, Roh TH, Kim MK, Kwon YC, Choi SM et al. Risk assessment of N-nitrosodiethylamine (NDEA) and N-nitrosodiethanolamine (NDELA) in cosmetics. J Toxicol Environ Health. 2018; 81:465–480.